Our Goal: Helping Cancer Patients Live Longer and Feel Better
Our lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications
Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. Our lead product candidate, IMM-1-104 is currently in a Phase 1/2a trial in patients with advanced solid tumors including pancreatic cancer.
Pipeline
Immuneering’s novel drug candidates are designed to improve tolerability by modulating cell signaling dynamics to selectively impact tumor cells and expand indications for a broader population of cancer patients.
Platform
We apply our proprietary platform and approach to develop our pipeline of orally administered small molecule drug programs for the treatment of cancer.
